Publisher Correction: Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer's disease

Marta Milà-Alomà^#^{1

2

3

4}, Nicholas J Ashton^#^{5

6

7

8}, Mahnaz Shekari^{1

2

3

4}, Gemma Salvadó^{1

2

3}, Paula Ortiz-Romero^{1

2}, Laia Montoliu-Gaya⁵, Andrea L Benedet^{5

9}, Thomas K Karikari^{5

10}, Juan Lantero-Rodriguez⁵, Eugeen Vanmechelen¹¹, Theresa A Day¹², Armand González-Escalante^{1

2}, Gonzalo Sánchez-Benavides^{1

2

3}, Carolina Minguillon^{1

2

3}, Karine Fauria^{1

3}, José Luis Molinuevo¹, Jeffrey L Dage^{12

13}, Henrik Zetterberg^{5

14

15

16}, Juan Domingo Gispert^{1

2

3

17}, Marc Suárez-Calvet^{18

19

20

21}, Kaj Blennow^{22

23}

Affiliations

¹ Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain.
² IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.
³ Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable, Instituto de Salud Carlos III, Madrid, Spain.
⁴ Universitat Pompeu Fabra, Barcelona, Spain.
⁵ Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, University of Gothenburg, Mölndal, Sweden.
⁶ Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden.
⁷ King's College London, Institute of Psychiatry, Psychology & Neuroscience, Maurice Wohl Clinical Neuroscience Institute, London, UK.
⁸ NIHR Biomedical Research Centre for Mental Health & Biomedical Research Unit for Dementia at South London & Maudsley NHS Foundation, London, UK.
⁹ Translational Neuroimaging Laboratory, McGill Centre for Studies in Aging, McGill University, Montreal, Quebec, Canada.
¹⁰ Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA.
¹¹ ADx NeuroSciences NV, Ghent, Belgium.
¹² Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA.
¹³ Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, IN, USA.
¹⁴ Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.
¹⁵ Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK.
¹⁶ UK Dementia Research Institute at UCL, London, UK.
¹⁷ Centro de Investigación Biomédica en Red Bioingeniería, Biomateriales y Nanomedicina, Madrid, Spain.
¹⁸ Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain. msuarez@barcelonabeta.org.
¹⁹ IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain. msuarez@barcelonabeta.org.
²⁰ Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable, Instituto de Salud Carlos III, Madrid, Spain. msuarez@barcelonabeta.org.
²¹ Servei de Neurologia, Hospital del Mar, Barcelona, Spain. msuarez@barcelonabeta.org.
²² Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, University of Gothenburg, Mölndal, Sweden. kaj.blennow@neuro.gu.se.
²³ Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden. kaj.blennow@neuro.gu.se.

^# Contributed equally.

PMID: 36100683
PMCID: PMC9499861
DOI: 10.1038/s41591-022-02037-1

Published Erratum

Publisher Correction: Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer's disease

Marta Milà-Alomà et al. Nat Med. 2022 Sep.

. 2022 Sep;28(9):1965.

doi: 10.1038/s41591-022-02037-1.

Authors

Affiliations

¹ Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain.
² IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.
³ Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable, Instituto de Salud Carlos III, Madrid, Spain.
⁴ Universitat Pompeu Fabra, Barcelona, Spain.
⁵ Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, University of Gothenburg, Mölndal, Sweden.
⁶ Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden.
⁷ King's College London, Institute of Psychiatry, Psychology & Neuroscience, Maurice Wohl Clinical Neuroscience Institute, London, UK.
⁸ NIHR Biomedical Research Centre for Mental Health & Biomedical Research Unit for Dementia at South London & Maudsley NHS Foundation, London, UK.
⁹ Translational Neuroimaging Laboratory, McGill Centre for Studies in Aging, McGill University, Montreal, Quebec, Canada.
¹⁰ Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA.
¹¹ ADx NeuroSciences NV, Ghent, Belgium.
¹² Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA.
¹³ Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, IN, USA.
¹⁴ Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.
¹⁵ Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK.
¹⁶ UK Dementia Research Institute at UCL, London, UK.
¹⁷ Centro de Investigación Biomédica en Red Bioingeniería, Biomateriales y Nanomedicina, Madrid, Spain.
¹⁸ Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain. msuarez@barcelonabeta.org.
¹⁹ IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain. msuarez@barcelonabeta.org.
²⁰ Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable, Instituto de Salud Carlos III, Madrid, Spain. msuarez@barcelonabeta.org.
²¹ Servei de Neurologia, Hospital del Mar, Barcelona, Spain. msuarez@barcelonabeta.org.
²² Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, University of Gothenburg, Mölndal, Sweden. kaj.blennow@neuro.gu.se.
²³ Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden. kaj.blennow@neuro.gu.se.

^# Contributed equally.

PMID: 36100683
PMCID: PMC9499861
DOI: 10.1038/s41591-022-02037-1

No abstract available

PubMed Disclaimer

Erratum for

Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer's disease.
Milà-Alomà M, Ashton NJ, Shekari M, Salvadó G, Ortiz-Romero P, Montoliu-Gaya L, Benedet AL, Karikari TK, Lantero-Rodriguez J, Vanmechelen E, Day TA, González-Escalante A, Sánchez-Benavides G, Minguillon C, Fauria K, Molinuevo JL, Dage JL, Zetterberg H, Gispert JD, Suárez-Calvet M, Blennow K. Milà-Alomà M, et al. Nat Med. 2022 Sep;28(9):1797-1801. doi: 10.1038/s41591-022-01925-w. Epub 2022 Aug 11. Nat Med. 2022. PMID: 35953717 Free PMC article.

Publication types

Actions

LinkOut - more resources

Full Text Sources

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Publisher Correction: Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer's disease

Affiliations

Publisher Correction: Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer's disease

Authors

Affiliations

Erratum for

Publication types

LinkOut - more resources

Full Text Sources